Inozyme Pharma, Inc.
INZYDelisted Jul 1, 2025- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001693011
Inozyme Pharma, Inc. was delisted on Jul 1, 2025; its insiders filed their last Form 4 on Jul 3, 2025; 87 institutions reported holding it in 13F filings for Q2 2025, worth $202.3M in total; no superinvestor held it.
13F holders, Q4 2022
Institutional positions in Inozyme Pharma, Inc. as of Dec 31, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 37
- −2 vs. Q3 2022
- Shares held
- 28.9M
- −1.90M (−6.1%) vs. Q3 2022
- Total value
- $30.4M
- −$52.3M (−63.2%) vs. Q3 2022
- New holders
- 6
- 11 more added
- Sold out
- 8
- 10 more reduced
Compare with Q3 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting INZY on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 0 | $0 |
| Q4 2025 | 0 | $0 |
| Q3 2025 | 0 | $0 |
| Q2 2025 | 87 | $202.3M |
| Q1 2025 | 97 | $42.5M |
| Q4 2024 | 105 | $145.1M |
| Q3 2024 | 89 | $285.5M |
| Q2 2024 | 90 | $240.1M |
| Q1 2024 | 89 | $382.0M |
| Q4 2023 | 80 | $213.3M |
| Q3 2023 | 77 | $204.6M |
| Q2 2023 | 74 | $190.3M |
| Q1 2023 | 50 | $183.4M |
| Q4 2022 | 37 | $30.4M |
| Q3 2022 | 39 | $82.7M |
| Q2 2022 | 47 | $149.4M |
| Q1 2022 | 50 | $71.2M |
| Q4 2021 | 51 | $118.2M |
| Q3 2021 | 52 | $202.7M |
| Q2 2021 | 50 | $337.1M |
| Q1 2021 | 55 | $379.4M |
Institutions, Q4 2022
Shares, value and share of portfolio for each institution holding Inozyme Pharma, Inc.; share changes are against Q3 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Sofinnova Investments, Inc. | 3,655,308 | $3.84M | 0.23% | 00.0% | Unchanged |
| Deep Track Capital, LP | 3,250,000 | $3.41M | 0.15% | 00.0% | Unchanged |
| Adage Capital Partners GP, L.L.C. | 3,100,138 | $3.26M | 0.01% | +503,466+19.4% | Added |
| Rock Springs Capital Management LP | 3,086,027 | $3.24M | 0.08% | +278,409+9.9% | Added |
| VR Adviser, LLC | 2,709,987 | $2.85M | 0.48% | 00.0% | Unchanged |
| Pivotal bioVenture Partners Investment Advisor LLC | 2,661,154 | $2.79M | 1.22% | 00.0% | Unchanged |
| NEA Management Company, LLC | 2,437,689 | $2.56M | 0.14% | −6,690−0.3% | Reduced |
| CHI Advisors LLC | 2,204,876 | $2.32M | 0.62% | +208,599+10.4% | Added |
| Sphera Funds Management Ltd. | 1,625,058 | $1.71M | 0.54% | +450,000+38.3% | Added |
| Vanguard Group Inc | 1,343,622 | $1.41M | 0.00% | +5590.0% | Added |
| Affinity Asset Advisors, LLC | 500,000 | $525.0K | 0.24% | +500,000 | New |
| BlackRock Inc. | 426,224 | $447.5K | 0.00% | −2,207−0.5% | Reduced |
| Millennium Management LLC | 297,936 | $313.0K | 0.00% | +127,752+75.1% | Added |
| Laurion Capital Management LP | 271,800 | $285.4K | 0.01% | 00.0% | Unchanged |
| Renaissance Technologies LLC | 258,900 | $272.0K | 0.00% | +103,500+66.6% | Added |
| Geode Capital Management, LLC | 233,126 | $244.0K | 0.00% | −559−0.2% | Reduced |
| MPM Oncology Impact Management LP | 230,500 | $242.0K | 0.06% | −430,644−65.1% | Reduced |
| Overbrook Management Corp | 219,326 | $230.3K | 0.07% | +150,000+216.4% | Added |
| Bridgeway Capital Management, LLC | 133,400 | $140.1K | 0.00% | 00.0% | Unchanged |
| State Street Corp | 76,355 | $80.2K | 0.00% | 00.0% | Unchanged |
| Northern Trust Corp | 45,943 | $48.2K | 0.00% | +5,639+14.0% | Added |
| State of Wisconsin Investment Board | 37,700 | $39.6K | 0.00% | −11,100−22.7% | Reduced |
| Dimensional Fund Advisors LP | 22,207 | $24.0K | 0.00% | −4,836−17.9% | Reduced |
| Bank of New York Mellon Corp | 20,243 | $21.3K | 0.00% | 00.0% | Unchanged |
| Parallel Advisors, LLC | 19,867 | $20.9K | 0.00% | +19,867 | New |
| Charles Schwab Investment Management Inc | 16,549 | $17.4K | 0.00% | 00.0% | Unchanged |
| Morgan Stanley | 13,146 | $13.8K | 0.00% | −9,138−41.0% | Reduced |
| Two Sigma Investments, LP | 12,383 | $13.0K | 0.00% | −800−6.1% | Reduced |
| Goldman Sachs Group Inc | 11,924 | $12.5K | 0.00% | +11,924 | New |
| Bank of America Corp | 7,105 | $7.46K | 0.00% | +4,178+142.7% | Added |
| Barclays PLC | 6,273 | $6.59K | 0.00% | −130−2.0% | Reduced |
| Tower Research Capital LLC (TRC) | 3,598 | $4.00K | 0.00% | +3,598 | New |
| UBS Group AG | 2,834 | $2.98K | 0.00% | +2,834 | New |
| Federated Hermes, Inc. | 1,381 | $1.45K | 0.00% | −152−9.9% | Reduced |
| Wells Fargo & Company | 162 | $170 | 0.00% | +5+3.2% | Added |
| JPMorgan Chase & Co | 60 | $0 | 0.00% | 00.0% | Unchanged |
| Simplex Trading, LLC | 137 | $0 | 0.00% | +137 | New |
| Deerfield Management Company, L.P. (Series C) | 0 | $0 | 0.00% | −2,090,436−100.0% | Sold out |
| Janus Henderson Group PLC | 0 | $0 | 0.00% | −705,577−100.0% | Sold out |
| FMR LLC | 0 | $0 | 0.00% | −609,380−100.0% | Sold out |
| UBS Oconnor LLC | 0 | $0 | 0.00% | −165,498−100.0% | Sold out |
| Walleye Capital LLC | 0 | $0 | 0.00% | −117,529−100.0% | Sold out |
| Citadel Advisors LLC | 0 | $0 | 0.00% | −110,648−100.0% | Sold out |
| Royal Bank of Canada | 0 | $0 | 0.00% | −690−100.0% | Sold out |
| Crewe Advisors LLC | 0 | $0 | 0.00% | −163−100.0% | Sold out |